The Solution

The technology solution is based on nature’s own model. The marine seaweed Delisea Pulchra has evolved a sophisticated chemical defence mechanism against bacterial and microbial contamination.

The Solution

The technology solution is based on nature’s own model. The marine seaweed Delisea Pulchra has evolved a sophisticated chemical defence mechanism against bacterial and microbial contamination.

Bacterial communication systems are key in the formation and development of biofilms.
Generating compounds called furanones, the balanced ecosystem of Delisea shields unwanted bacterial communication of microbial invaders. This in turn prevents the biofilm formation and contamination of its surfaces, thereby ensuring healthy growth.

Bacterial communication systems are key in the formation and development of biofilms.
Generating compounds called furanones, the balanced ecosystem of Delisea shields unwanted bacterial communication of microbial invaders. This in turn prevents the biofilm formation and contamination of its surfaces, thereby ensuring healthy growth.

Inspired by the natural compounds produced through the evolution of Delisea, Unilever plc has been developing biomimetic technology to combat biofilm formation for the past 10 years.

The result of this work is a substantial intellectual property portfolio of furanone derivatives, called lactams.

Lactams, at ppm levels, interfere with signalling activities among bacteria with a primary bacteriostatic effect. Importantly, lactams have been shown to inhibit biosensing between bacteria and can further influence the bacteria to be less invasive.

Crucially, research has shown that this effect has not only had impact across gram positive and negative bacteria, but also yeast, fungi and algae show sensitivity to the lactam technology. This demonstrates the potential for the lactam technology to be effective on multi-species biofilms.

Leveraging millions of years of Delisea’s evolution has therefore resulted in anti-biofilm technology capable of solving a number of industrial, consumer and healthcare problems. This approach also targets challenges in bacterial resistance as well as reduction of environmental damage caused by microbial contamination, the hallmarks of a sustainable antibacterial strategy.

Penrhos Bio has exclusive licence to this unique IP portfolio including use-specific patents to exploit this technology across a range of targeted commercial applications.

Inspired by the natural compounds produced through the evolution of Delisea, Unilever plc has been developing biomimetic technology to combat biofilm formation for the past 10 years.

The result of this work is a substantial intellectual property portfolio of furanone derivatives, called lactams.

Lactams, at ppm levels, interfere with signalling activities among bacteria with a primary bacteriostatic effect. Importantly, lactams have been shown to inhibit biosensing between bacteria and can further influence the bacteria to be less invasive.

Crucially, research has shown that this effect has not only had impact across gram positive and negative bacteria, but also yeast, fungi and algae show sensitivity to the lactam technology. This demonstrates the potential for the lactam technology to be effective on multi-species biofilms.

Leveraging millions of years of Delisea’s evolution has therefore resulted in anti-biofilm technology capable of solving a number of industrial, consumer and healthcare problems. This approach also targets challenges in bacterial resistance as well as reduction of environmental damage caused by microbial contamination, the hallmarks of a sustainable antibacterial strategy.

Penrhos Bio has exclusive licence to this unique IP portfolio including use-specific patents to exploit this technology across a range of targeted commercial applications.